Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Oliver Waidmann

Showing results (1-10 of 112) with videos related to

Pageof 12
Sort By:
Expert Opinion on Biological Therapy|July 12, 2018
Recent developments with immunotherapy for hepatocellular carcinomaOliver Waidmann
Journal of Hepatocellular Carcinoma|October 6, 2016
Role of regorafenib as second-line therapy and landscape of investigational treatment options in advanced hepatocellular carcinomaJörg Trojan, Oliver Waidmann
European Journal of Cancer (Oxford, England : 1990)|December 20, 2016
Reply to the Letter to the Editor concerning 'High levels of the soluble programmed death-ligand identify hepatocellular carcinoma patients with a poor prognosis'Fabian Finkelmeier, Oliver Waidmann
Expert Opinion on Investigational Drugs|June 26, 2015
Novel drugs in clinical development for hepatocellular carcinomaOliver Waidmann, Jörg Trojan
Zeitschrift Fur Gastroenterologie|April 5, 2017
Update on cholangiocarcinoma: potential impact of genomic studies on clinical managementDirk Walter, Sylvia Hartmann, Oliver Waidmann
Zeitschrift Fur Gastroenterologie|June 17, 2020
[Systemic Chemotherapy of gallbladder carcinoma - simply the same as for cholangiocarcinoma?]Dirk Walter, Jörg Trojan, Oliver Waidmann
Expert Review of Anticancer Therapy|October 12, 2018
Nivolumab for the treatment of hepatocellular carcinomaFabian Finkelmeier, Oliver Waidmann, Joerg Trojan
Gastroenterology|February 1, 2011
NEMO catches the FOXOliver Waidmann, Albrecht Piiper, Stefan Zeuzem
Deutsche Medizinische Wochenschrift (1946)|September 25, 2015
[New insights into epidemiology may promote screening in Cholangiocarcinoma]Jörg Gerhard Albert, Oliver Waidmann, Tania Mara Welzel
Zeitschrift Fur Gastroenterologie|June 12, 2018
Sequence therapy in metastatic pancreatic cancerOliver Waidmann, Uwe Pelzer, Stefan Boeck, et al.
Pageof 12

Showing results (1-10 of 112) with videos related to

Sort By:
Pageof 12
Expert Opinion on Biological Therapy|July 12, 2018
Recent developments with immunotherapy for hepatocellular carcinomaOliver Waidmann
Journal of Hepatocellular Carcinoma|October 6, 2016
Role of regorafenib as second-line therapy and landscape of investigational treatment options in advanced hepatocellular carcinomaJörg Trojan, Oliver Waidmann
European Journal of Cancer (Oxford, England : 1990)|December 20, 2016
Reply to the Letter to the Editor concerning 'High levels of the soluble programmed death-ligand identify hepatocellular carcinoma patients with a poor prognosis'Fabian Finkelmeier, Oliver Waidmann
Expert Opinion on Investigational Drugs|June 26, 2015
Novel drugs in clinical development for hepatocellular carcinomaOliver Waidmann, Jörg Trojan
Zeitschrift Fur Gastroenterologie|April 5, 2017
Update on cholangiocarcinoma: potential impact of genomic studies on clinical managementDirk Walter, Sylvia Hartmann, Oliver Waidmann
Zeitschrift Fur Gastroenterologie|June 17, 2020
[Systemic Chemotherapy of gallbladder carcinoma - simply the same as for cholangiocarcinoma?]Dirk Walter, Jörg Trojan, Oliver Waidmann
Expert Review of Anticancer Therapy|October 12, 2018
Nivolumab for the treatment of hepatocellular carcinomaFabian Finkelmeier, Oliver Waidmann, Joerg Trojan
Gastroenterology|February 1, 2011
NEMO catches the FOXOliver Waidmann, Albrecht Piiper, Stefan Zeuzem
Deutsche Medizinische Wochenschrift (1946)|September 25, 2015
[New insights into epidemiology may promote screening in Cholangiocarcinoma]Jörg Gerhard Albert, Oliver Waidmann, Tania Mara Welzel
Zeitschrift Fur Gastroenterologie|June 12, 2018
Sequence therapy in metastatic pancreatic cancerOliver Waidmann, Uwe Pelzer, Stefan Boeck, et al.
Pageof 12